London Daily

Focus on the big picture.
Tuesday, Jul 29, 2025

MS charities decry UK postcode lottery for ‘life-changing’ drug

MS charities decry UK postcode lottery for ‘life-changing’ drug

Nearly 70,000 estimated to be missing out on drug available on NHS in Wales and Scotland
People with multiple sclerosis are paying up to £600 a month for a “life-changing” drug that is available on the NHS in Wales and Scotland but not in England.

Charities estimate that tens of thousands of people with MS are missing out on fampridine, which can improve a person’s ability to walk and reduce the risk of falling over.

They say the “postcode lottery” within Britain around access to the drug is “grossly unfair” to patients in England, who are being forced to live with MS’s very debilitating symptoms – which can include problems with vision, arm and leg movement, sensation and balance.

The senior Labour MP Dame Margaret Hodge has written to the health secretary, Sajid Javid, urging him to ensure that the medication is available to anyone who needs it.

Her intervention came after her constituent Steven Brooks’s ability to walk improved markedly after receiving fampridine as part of a clinical trial but whose health then declined when the trial ended and his hospital could not provide it.

“It is grossly unfair that people with MS are being denied access to fampridine – a potentially life-changing treatment – based purely on where they live in the UK,” said Phillip Anderson, the head of policy at the MS Society.

“MS is relentless, painful and disabling, but we know this treatment can make a significant difference to many people’s symptoms, including helping them to walk and manage MS fatigue.”

The disparity in access has arisen because the National Institute for Health and Care Excellence (Nice), which advises the government and NHS in England, believes fampridine does not represent value for money whereas its equivalent bodies in Wales and Scotland have recommended it.

The MS Society estimates that about 40,000 MS patients in England who would benefit from taking the drug cannot get it because of Nice’s ruling. About 200 people there have obtained it on the NHS and only after submitting an “individual funding request” – an appeal against being denied an expensive form of treatment – and showing they have exceptional need for it.

But the society says they represent only 0.5% of those who may enjoy a boost to their walking ability and quality of life if they could get fampridine on the NHS.

Biogen, which makes the medication, says an even larger number of people in England – about 65,000 – could improve their health if they could obtain the drug, and another 3,000 in Northern Ireland.

The MS Trust said patients were paying between £200 and £600 a month for the drug privately.

David Martin, the trust’s chief executive, said: “In England people with MS are being forced to make difficult choices on whether to pay for a medication that they could get for free in other parts of the UK. We at the MS Trust don’t think this is fair.

“We know that fampridine can make a difference to some people with MS who experience walking difficulties and the MS Trust would like to see fair access to this treatment across the UK.”

In her letter, Hodge asked Javid why NHS England had not been able to secure a discount on the cost of the drug from Biogen after the Scottish NHS agreed a deal to ensure its availability.

“It is not acceptable to find NHS England lagging behind and failing to offer access to fampridine for free. This failure has created a postcode lottery for MS sufferers that has severely impacted on the life of my constituent.”

Nice is updating its guidance on treating MS, which charities and patients hope will lead to the drug becoming free on the NHS in England. That is expected in 2022.

The Department of Health and Social Care said it sympathised with patients denied the drug but backed Nice’s judgment.

“We want all patients to have access to first-rate, innovative medicines and sympathise with those dealing with challenging conditions like multiple sclerosis,” a spokesperson said.

“Nice is world-renowned for its expertise in identifying effective treatments at a price that is fair to the NHS and taxpayers. They found there is currently not enough evidence on the effectiveness of this medicine compared to other effective treatments to recommend it for patients.

“We want to reassure people that Nice keeps its guidance under review. It’s currently reviewing its recommendations on fampridine and expects to publish updated guidelines next year.”
Newsletter

Related Articles

0:00
0:00
Close
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
×